{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:03:57Z","timestamp":1793156637378,"version":"4.5.0"},"reference-count":86,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T00:00:00Z","timestamp":1509062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Acute kidney injury due to high-dose methotrexate (HDMTX) is a serious, life-threatening toxicity that can occur in pediatric and adult patients. Glucarpidase is a treatment approved by the Food and Drug Administration for high methotrexate concentrations in the context of kidney dysfunction, but the guidelines for when to use it are unclear. An expert panel was convened to provide specific, expert consensus guidelines for the use of glucarpidase in patients who develop HDMTX-induced nephrotoxicity and delayed methotrexate excretion. The guideline provides recommendations to identify the population of patients who would benefit from glucarpidase rescue by more precisely defining the absolute methotrexate concentrations associated with risk for severe or life-threatening toxicity at several time points after the start of an HDMTX infusion. For an HDMTX infusion \u226424 hours, if the 36-hour concentration is above 30 \u00b5M, 42-hour concentration is above 10 \u00b5M, or 48-hour concentration is above 5 \u00b5M and the serum creatinine is significantly elevated relative to the baseline measurement (indicative of HDMTX-induced acute kidney injury), glucarpidase may be indicated. After a 36- to 42-hour HDMTX infusion, glucarpidase may be indicated when the 48-hour methotrexate concentration is above 5 \u00b5M. Administration of glucarpidase should optimally occur within 48\u201360 hours from the start of the HDMTX infusion, because life-threatening toxicities may not be preventable beyond this time point.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Practice<\/jats:title>\n                    <jats:p>Glucarpidase is a rarely used medication that is less effective when given after more than 60 hours of exposure to high-dose methotrexate, so predicting early which patients will need it is imperative. There are no currently available consensus guidelines for the use of this medication. The indication on the label does not give specific methotrexate concentrations above which it should be used. An international group of experts was convened to develop a consensus guideline that was specific and evidence-based to identify the population of patients who would benefit from glucarpidase.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0243","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T14:30:25Z","timestamp":1509114625000},"page":"52-61","source":"Crossref","is-referenced-by-count":215,"title":["Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance"],"prefix":"10.1093","volume":"23","author":[{"given":"Laura B.","family":"Ramsey","sequence":"first","affiliation":[{"name":"Division of Research in Patient Services, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA"},{"name":"Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank M.","family":"Balis","sequence":"additional","affiliation":[{"name":"Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen M.","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjeld","family":"Schmiegelow","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, and Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Pauley","sequence":"additional","affiliation":[{"name":"Pharmaceutical Department, St. Jude Children's Research Hospital, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archie","family":"Bleyer","sequence":"additional","affiliation":[{"name":"Department of Radiation Medicine, Oregon Health and Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte C.","family":"Widemann","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Askenazi","sequence":"additional","affiliation":[{"name":"Pediatric and Infant Center for Acute Nephrology, Professor of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Bergeron","sequence":"additional","affiliation":[{"name":"Hyundai Cancer Institute, Children's Hospital of Orange County, Orange, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushree","family":"Shirali","sequence":"additional","affiliation":[{"name":"Assistant Professor of Medicine, Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Medizinische Klinik mit Schwerpunkt H\u00e4matologie, Onkologie und Tumorimmunologie, Charit\u00e9 Campus Benjamin Franklin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A.","family":"Vinks","sequence":"additional","affiliation":[{"name":"Division of Research in Patient Services, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA"},{"name":"Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Heldrup","sequence":"additional","affiliation":[{"name":"Childhood Cancer and Research Unit, University Children's Hospital, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,10,27]]},"reference":[{"key":"2021122509423146900_onco12295-bib-0001","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00280-008-0772-0","article-title":"Renal dysfunction during and after high-dose methotrexate","volume":"63","author":"Green","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122509423146900_onco12295-bib-0002","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/0006-2952(68)90033-6","article-title":"The enzymatic hydrolysis of folate analogues","volume":"17","author":"Goldman","year":"1968","journal-title":"Biochem Pharmacol"},{"key":"2021122509423146900_onco12295-bib-0003","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1016\/S0021-9258(18)99594-3","article-title":"The enzymatic hydrolysis of methotrexate and folic acid","volume":"242","author":"Levy","year":"1967","journal-title":"J Biol Chem"},{"key":"2021122509423146900_onco12295-bib-0004","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0022-3565(24)39150-5","article-title":"Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-n 10-methylpteroic acid","volume":"294","author":"Widemann","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"2021122509423146900_onco12295-bib-0005","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1634\/theoncologist.11-6-694","article-title":"Understanding and managing methotrexate nephrotoxicity","volume":"11","author":"Widemann","year":"2006","journal-title":"The Oncologist"},{"key":"2021122509423146900_onco12295-bib-0006","author":"BTG International, Inc","year":"2012"},{"key":"2021122509423146900_onco12295-bib-0007","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1080\/10428190600942769","article-title":"Very high-dose methotrexate (33.6 g\/m2) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: Results of National Cancer Institute\/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P","volume":"47","author":"Nathan","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"2021122509423146900_onco12295-bib-0008","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1365-2710.2008.00966.x","article-title":"Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: A concurrent analysis of the serum and urine concentration data. J","volume":"33","author":"Fukuhara","year":"2008","journal-title":"Clin Pharm Ther"},{"key":"2021122509423146900_onco12295-bib-0009","first-page":"139","volume-title":"Antifolates","author":"Messmann","year":"2001"},{"key":"2021122509423146900_onco12295-bib-0010","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00280-010-1259-3","article-title":"Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma","volume":"66","author":"Mir","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122509423146900_onco12295-bib-0011","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/FPC.0b013e328343dd93","article-title":"PharmGKB summary: Methotrexate pathway","volume":"21","author":"Mikkelsen","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"2021122509423146900_onco12295-bib-0012","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1182\/blood-2012-08-452839","article-title":"Genome-wide study of methotrexate clearance replicates SLCO1B1","volume":"121","author":"Ramsey","year":"2013","journal-title":"Blood"},{"key":"2021122509423146900_onco12295-bib-0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/gr.129668.111","article-title":"Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition","volume":"22","author":"Ramsey","year":"2012","journal-title":"Genome Res"},{"key":"2021122509423146900_onco12295-bib-0014","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/sj.leu.2401673","article-title":"Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia","volume":"14","author":"Wall","year":"2000","journal-title":"Leukemia"},{"key":"2021122509423146900_onco12295-bib-0015","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/BF00686272","article-title":"Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma","volume":"33","author":"Pignon","year":"1994","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122509423146900_onco12295-bib-0016","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00280-002-0552-1","article-title":"High-dose methotrexate: On the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL)","volume":"51","author":"Sk\u00e4rby","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122509423146900_onco12295-bib-0017","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1517\/14740338.7.2.147","article-title":"Drug-induced crystal nephropathy: An update","volume":"7","author":"Yarlagadda","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"2021122509423146900_onco12295-bib-0018","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1002\/cncr.27378","article-title":"Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients","volume":"118","author":"Christensen","year":"2012","journal-title":"Cancer"},{"key":"2021122509423146900_onco12295-bib-0019","doi-asserted-by":"crossref","first-page":"e26395","DOI":"10.1002\/pbc.26395","article-title":"Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia","volume":"64","author":"Svahn","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"2021122509423146900_onco12295-bib-0020","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/cncr.20255","article-title":"High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma","volume":"100","author":"Widemann","year":"2004","journal-title":"Cancer"},{"key":"2021122509423146900_onco12295-bib-0021","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2009.25.4540","article-title":"Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: Clinical and pharmacologic factors affecting outcome","volume":"28","author":"Widemann","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122509423146900_onco12295-bib-0022","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/pbc.25395","article-title":"Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients","volume":"62","author":"Scott","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"2021122509423146900_onco12295-bib-0023","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/phar.1360","article-title":"Efficacy of glucarpidase (carboxypeptidase G2) in patients with acute kidney injury after high-dose methotrexate therapy","volume":"34","author":"Widemann","year":"2014","journal-title":"Pharmacotherapy"},{"key":"2021122509423146900_onco12295-bib-0024","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1056\/NEJMra1214243","article-title":"Acute kidney injury and chronic kidney disease as interconnected syndromes","volume":"371","author":"Chawla","year":"2014","journal-title":"N Engl J Med"},{"key":"2021122509423146900_onco12295-bib-0025","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1172\/JCI108308","article-title":"7-hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate","volume":"57","author":"Jacobs","year":"1976","journal-title":"J Clin Invest"},{"key":"2021122509423146900_onco12295-bib-0026","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0304-3835(80)90117-2","article-title":"The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy","volume":"9","author":"Lankelma","year":"1980","journal-title":"Cancer Lett"},{"key":"2021122509423146900_onco12295-bib-0027","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1056\/NEJMc1507547","article-title":"Acute methotrexate-induced crystal nephropathy","volume":"373","author":"Garneau","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122509423146900_onco12295-bib-0028","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF00254177","article-title":"Methotrexate administered by 6-h and 24-h infusion: A pharmacokinetic comparison","volume":"22","author":"Borsi","year":"1988","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122509423146900_onco12295-bib-0029","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/pbc.10443","article-title":"Methotrexate pharmacokinetics and survival in osteosarcoma","volume":"42","author":"Aquerreta","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"2021122509423146900_onco12295-bib-0030","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/ejh.12097","article-title":"Risk group assignment differs for children and adults 1\u201345 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol","volume":"90","author":"Toft","year":"2013","journal-title":"Eur J Haematol"},{"key":"2021122509423146900_onco12295-bib-0031","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1001\/archinte.1978.03630320078028","article-title":"Methotrexate-induced renal failure and ineffectiveness of peritoneal dialysis","volume":"138","author":"Ahmad","year":"1978","journal-title":"Arch Intern Med"},{"key":"2021122509423146900_onco12295-bib-0032","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/BF00625045","article-title":"Toxicity associated with combination chemotherapy for osteosarcoma: A report of the cooperative osteosarcoma study (COSS 80)","volume":"106","author":"J\u00fcrgens","year":"1983","journal-title":"J Cancer Res Clin Oncol"},{"key":"2021122509423146900_onco12295-bib-0033","first-page":"3574","article-title":"Interaction of methotrexate polyglutamates and dihydrofolate during leucovorin rescue in a human breast cancer cell line (MCF-7)","volume":"50","author":"Allegra","year":"1990","journal-title":"Cancer Res"},{"key":"2021122509423146900_onco12295-bib-0034","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2141.2009.07765.x","article-title":"Advances in individual prediction of methotrexate toxicity: A review","volume":"146","author":"Schmiegelow","year":"2009","journal-title":"Br J Haematol"},{"key":"2021122509423146900_onco12295-bib-0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF00401438","article-title":"Theoretically required urinary flow during high-dose methotrexate infusion","volume":"13","author":"Sasaki","year":"1984","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122509423146900_onco12295-bib-0036","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1200\/JCO.1994.12.8.1667","article-title":"Patient characteristics associated with high-risk methotrexate concentrations and toxicity","volume":"12","author":"Relling","year":"1994","journal-title":"J Clin Oncol"},{"key":"2021122509423146900_onco12295-bib-0037","first-page":"203","article-title":"Rescue\u201d techniques in cancer chemotherapy: Use of leucovorin and other rescue agents after methotrexate treatment","volume":"4","author":"Bertino","year":"1977","journal-title":"Semin Oncol"},{"key":"2021122509423146900_onco12295-bib-0038","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/239395b0","article-title":"Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity","volume":"239","author":"Chabner","year":"1972","journal-title":"Nature"},{"key":"2021122509423146900_onco12295-bib-0039","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1200\/JCO.1992.10.8.1359","article-title":"Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys","volume":"10","author":"Adamson","year":"1992","journal-title":"J Clin Oncol"},{"key":"2021122509423146900_onco12295-bib-0040","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1128\/jb.156.3.1222-1227.1983","article-title":"Molecular cloning of the Pseudomonas carboxypeptidase G2 gene and its expression in Escherichia coli and Pseudomonas putida","volume":"156","author":"Minton","year":"1983","journal-title":"J Bacteriol"},{"key":"2021122509423146900_onco12295-bib-0041","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1432-1033.1985.tb08860.x","article-title":"Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16","volume":"148","author":"Sherwood","year":"1985","journal-title":"Eur J Biochem"},{"key":"2021122509423146900_onco12295-bib-0042","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1634\/theoncologist.12-11-1299","article-title":"Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy","volume":"12","author":"Schwartz","year":"2007","journal-title":"The Oncologist"},{"key":"2021122509423146900_onco12295-bib-0043","author":"BTG International, Inc"},{"key":"2021122509423146900_onco12295-bib-0044","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1080\/1042819021000032953","article-title":"Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy","volume":"43","author":"Krause","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"2021122509423146900_onco12295-bib-0045","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/sj.bjc.6602337","article-title":"Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure","volume":"92","author":"Buchen","year":"2005","journal-title":"Br J Cancer"},{"key":"2021122509423146900_onco12295-bib-0046","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0091270007311571","article-title":"Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function","volume":"48","author":"Phillips","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"2021122509423146900_onco12295-bib-0047","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1200\/JCO.1996.14.7.2145","article-title":"Carboxypeptidase G2 rescue after high-dose methotrexate","volume":"14","author":"DeAngelis","year":"1996","journal-title":"J Clin Oncol"},{"key":"2021122509423146900_onco12295-bib-0048","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/jnci\/djh270","article-title":"Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2","volume":"96","author":"Widemann","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"2021122509423146900_onco12295-bib-0049","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/00043426-199608000-00014","article-title":"Intrathecal leucovorin after intrathecal methotrexate overdose","volume":"18","author":"Jardine","year":"1996","journal-title":"J Pediatr Hematol Oncol"},{"key":"2021122509423146900_onco12295-bib-0050","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/clinchem\/42.1.39","article-title":"Evaluation of clinical assays for measuring high-dose methotrexate in plasma","volume":"42","author":"Albertioni","year":"1996","journal-title":"Clin Chem"},{"key":"2021122509423146900_onco12295-bib-0051","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.1997.15.5.2125","article-title":"Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction","volume":"15","author":"Widemann","year":"1997","journal-title":"J Clin Oncol"},{"key":"2021122509423146900_onco12295-bib-0052","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/S0272-6386(96)90384-4","article-title":"Effective clearance of methotrexate using high-flux hemodialysis membranes","volume":"28","author":"Wall","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"2021122509423146900_onco12295-bib-0053","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/sdi.12220","article-title":"What is the best therapy for toxicity in the setting of methotrexate-associated acute kidney injury: High-flux hemodialysis or carboxypeptidase G2?","volume":"27","author":"Kumar","year":"2014","journal-title":"Semin Dial"},{"key":"2021122509423146900_onco12295-bib-0054","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/cpt1978233351","article-title":"Hemoperfusion for methotrexate removal","volume":"23","author":"Gibson","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"2021122509423146900_onco12295-bib-0055","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/1097-0142(19880901)62:5<884::AID-CNCR2820620506>3.0.CO;2-A","article-title":"Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion","volume":"62","author":"Relling","year":"1988","journal-title":"Cancer"},{"key":"2021122509423146900_onco12295-bib-0056","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00467-002-0946-7","article-title":"Effective removal of methotrexate by high-flux hemodialysis","volume":"17","author":"Saland","year":"2002","journal-title":"Pediatr Nephrol"},{"key":"2021122509423146900_onco12295-bib-0057","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.1999.17.5.1589","article-title":"High-dose leucovorin as sole therapy for methotrexate toxicity","volume":"17","author":"Flombaum","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122509423146900_onco12295-bib-0058","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/08880010390242898","article-title":"Progression of osteosarcoma after high-dose methotrexate: Over-rescue by folinic acid","volume":"20","author":"Cohen","year":"2003","journal-title":"Pediatr Hematol Oncol"},{"key":"2021122509423146900_onco12295-bib-0059","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1038\/sj.leu.2404404","article-title":"High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia","volume":"20","author":"Sk\u00e4rby","year":"2006","journal-title":"Leukemia"},{"key":"2021122509423146900_onco12295-bib-0060","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1373\/clinchem.2005.061150","article-title":"Pretreatment plasma folate modulates the pharmacodynamic effect of high-dose methotrexate in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma: \u201cFolate overrescue\u201d concept revisited","volume":"52","author":"Sterba","year":"2006","journal-title":"Clin Chem"},{"key":"2021122509423146900_onco12295-bib-0061","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/CAD.0b013e32835b8662","article-title":"Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia","volume":"24","author":"Csordas","year":"2013","journal-title":"Anticancer Drugs"},{"key":"2021122509423146900_onco12295-bib-0062","first-page":"851","article-title":"Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy","volume":"10","author":"Bacci","year":"2003","journal-title":"Oncol Rep"},{"key":"2021122509423146900_onco12295-bib-0063","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/annonc\/mdi075","article-title":"High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma","volume":"16","author":"Jahnke","year":"2005","journal-title":"Ann Oncol"},{"key":"2021122509423146900_onco12295-bib-0064","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3109\/10428194.2013.840780","article-title":"High incidence of methotrexate associated renal toxicity in patients with lymphoma: A retrospective analysis","volume":"55","author":"May","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"2021122509423146900_onco12295-bib-0065","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nrneph.2009.97","article-title":"Chemotherapy-associated renal dysfunction","volume":"5","author":"Sahni","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"2021122509423146900_onco12295-bib-0066","first-page":"1","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2021122509423146900_onco12295-bib-0067","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1136\/bmj.324.7352.1497","article-title":"Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate","volume":"324","author":"Tr\u00f6ger","year":"2002","journal-title":"BMJ"},{"key":"2021122509423146900_onco12295-bib-0068","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/clinchem\/42.8.1322","article-title":"Concepts in use of high-dose methotrexate therapy","volume":"42","author":"Treon","year":"1996","journal-title":"Clin Chem"},{"key":"2021122509423146900_onco12295-bib-0069","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2125.2008.03303.x","article-title":"Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy","volume":"67","author":"Suzuki","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"2021122509423146900_onco12295-bib-0070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2125.2005.02513.x","article-title":"Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients","volume":"62","author":"Joerger","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"2021122509423146900_onco12295-bib-0071","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s11096-008-9204-9","article-title":"Interaction between methotrexate and omeprazole in an adolescent with leukemia: A case report","volume":"30","author":"Bauters","year":"2008","journal-title":"Pharm World Sci"},{"key":"2021122509423146900_onco12295-bib-0072","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00007691-199310000-00004","article-title":"Pharmacokinetic interaction between high-dose methotrexate and amoxycillin","volume":"15","author":"Ronchera","year":"1993","journal-title":"Ther Drug Monit"},{"key":"2021122509423146900_onco12295-bib-0073","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S0140-6736(86)90786-5","article-title":"Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen","author":"Thyss","year":"1986","journal-title":"Lancet"},{"key":"2021122509423146900_onco12295-bib-0074","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1093\/ndt\/gfn503","article-title":"Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: A significant number result from unrecognized co-administration of several drugs","volume":"23","author":"Miguel","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2021122509423146900_onco12295-bib-0075","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/jcpt.12298","article-title":"High methotrexate exposure and toxicity in children with t(9;22) positive acute lymphoblastic leukaemia treated with imatinib","volume":"40","author":"Loue","year":"2015","journal-title":"J Clin Pharm Ther"},{"key":"2021122509423146900_onco12295-bib-0076","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1021\/jf8029918","article-title":"Glycyrrhizin and licorice significantly affect the pharmacokinetics of methotrexate in rats","volume":"57","author":"Lin","year":"2009","journal-title":"J Agric Food Chem"},{"key":"2021122509423146900_onco12295-bib-0077","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/S1470-2045(16)30035-3","article-title":"Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: A Delphi consensus","volume":"17","author":"Schmiegelow","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122509423146900_onco12295-bib-0078","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/MPH.0000000000000606","article-title":"Prophylactic trimethoprim-sulfamethoxazole does not affect pharmacokinetics or pharmacodynamics of methotrexate","volume":"38","author":"Watts","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"key":"2021122509423146900_onco12295-bib-0079","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/FPC.0b013e328343dd93","article-title":"PharmGKB summary: Methotrexate pathway","volume":"21","author":"Mikkelsen","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"2021122509423146900_onco12295-bib-0080","first-page":"6","article-title":"Mechanisms of the effects of methotrexate","volume":"45","author":"Cronstein","year":"1996","journal-title":"Bull Rheum Dis"},{"key":"2021122509423146900_onco12295-bib-0081","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/MPH.0b013e3181868570","article-title":"Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia","volume":"30","author":"Davidsen","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"key":"2021122509423146900_onco12295-bib-0082","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1172\/JCI112088","article-title":"Polyglutamation of methotrexate. Is methotrexate a prodrug?","volume":"76","author":"Chabner","year":"1985","journal-title":"J Clin Invest"},{"key":"2021122509423146900_onco12295-bib-0083","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/BF00256175","article-title":"Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukemia during maintenance treatment","volume":"16","author":"Schr\u00f8der","year":"1986","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122509423146900_onco12295-bib-0084","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF00273386","article-title":"Methotrexate pharmacokinetics in age-fractionated erythrocytes","volume":"18","author":"Schr\u00f8der","year":"1986","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122509423146900_onco12295-bib-0085","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/BF00296254","article-title":"Methotrexate kinetics in myeloid bone marrow cells and peripheral neutrophils","volume":"19","author":"Schr\u00f8der","year":"1987","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122509423146900_onco12295-bib-0086","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/10428190701824569","article-title":"Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells","volume":"49","author":"Fotoohi","year":"2008","journal-title":"Leuk Lymphoma"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0243","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0243","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/1\/52\/41914643\/oncolo_23_1_52.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/1\/52\/41914643\/oncolo_23_1_52.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T15:38:34Z","timestamp":1750952314000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/1\/52\/6438709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,27]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,10,27]]},"published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0243","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,1,1]]},"published":{"date-parts":[[2017,10,27]]}}}